Drug Profile
Research programme: kynurenine aminotransferase II inhibitors - Pfizer
Alternative Names: Bicyclic and tricyclic compounds as KAT II inhibitors - Pfizer; KAT II inhibitors - PfizerLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Pfizer
- Class Heterocyclic compounds
- Mechanism of Action Kynurenine-oxoglutarate transaminase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Schizophrenia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Schizophrenia in USA (SC)
- 17 Nov 2010 Preclinical trials in Schizophrenia in USA (SC)
- 17 Nov 2010 Pharmacodynamics data from a preclinical trial in Schizophrenia presented at the 40th Annual Meeting of the Society for Neuroscience (SfN-2010) ,